Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating expenses:
Research and development	$ 23,854	$ 5,514
General and administrative	8,236	70
Total operating expenses	32,090	5,584
Loss from operations	(32,090)	(5,584)
Other income (expense):
Change in fair value of preferred stock tranche liability	200	180
Interest income	66
Interest expense		(27)
Total other income, net	66	153
Net loss	$ (32,024)	$ (5,431)
Net loss per common share, basic and diluted	$ (0.87)	$ (0.50)
Weighted average common shares outstanding, basic and diluted	36,992,377	10,894,999